Business Context and Reporting Period
Company: IDEAYA Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date: April 13, 2026
Subject: Clinical Update on the OptimUM-02 Phase 2/3 registrational trial for darovasertib in combination with crizotinib for first-line metastatic uveal melanoma (mUM).
Key Financial Metrics
This filing is a clinical update and does not contain financial statements. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Results
The Company announced topline results from the OptimUM-02 trial involving 313 patients (210 in the darovasertib combination arm vs. 103 in the investigator choice of therapy [ICT] arm). The darovasertib combination met the primary endpoint with statistically significant improvements:
- Progression-Free Survival (PFS): Median PFS was 6.9 months for the darovasertib combination versus 3.1 months for ICT. This represents a 58% reduction in the risk of disease progression (Hazard Ratio: 0.42; p-value <0.0001).
- Overall Response Rate (ORR): 37.1% for the darovasertib combination versus 5.8% for ICT (p-value <0.0001).
- Complete Responses: 5 observed in the darovasertib arm; 0 in the ICT arm.
- Duration of Response (DOR): Median DOR was 6.8 months in the darovasertib arm.
- Overall Survival (OS): Data is not mature, but an early trend of improvement was observed.
- Safety: The combination was generally well-tolerated. Most common Grade 3+ adverse events included diarrhea, syncope, and hypotension. Treatment-related serious adverse events were in the single-digit percent range.
Guidance, Outlook, and Risks
Regulatory Outlook: Based on these data, the Company targets submitting a New Drug Application (NDA) to the U.S. FDA in the second half of 2026. Additional data details are planned for presentation at a major medical conference in 2026.
Risks and Uncertainties: The filing includes standard forward-looking statement disclaimers. Risks include uncertainties in drug development, clinical trial enrollment, safety outcomes, regulatory decisions, manufacturing, competition, and the sufficiency of financial resources to fund operations.
Investor Verification Checklist
- Verify the specific statistical methodology and confidence intervals for the PFS and ORR results in the full clinical study report.
- Confirm the exact timeline for the NDA submission in the second half of 2026 and any potential FDA feedback.
- Review the Company's most recent Form 10-K (filed February 17, 2026) for current cash runway and liquidity status to fund the NDA process and potential commercialization.
- Monitor upcoming presentations at major medical conferences for detailed safety data and subgroup analyses.
- Assess the competitive landscape for first-line mUM treatments, specifically the efficacy of the ICT arm components (ipilimumab/nivolumab and pembrolizumab) in real-world settings.